Cargando…

Therapies for acute myeloid leukemia: vosaroxin

Vosaroxin, a quinolone-derivative chemotherapeutic agent, was considered a promising drug for the treatment of acute myeloid leukemia (AML). Early-stage clinical trials with this agent led to a large randomized double-blind placebo-controlled study of vosaroxin in combination with intermediate-dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sayar, Hamid, Bashardoust, Parvaneh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558588/ https://www.ncbi.nlm.nih.gov/pubmed/28860803 http://dx.doi.org/10.2147/OTT.S121477

Ejemplares similares

Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia
por: Jamieson, Gene C., et al.
Publicado: (2016)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Radiosensitization by the novel DNA intercalating agent vosaroxin
por: Gordon, Ira K, et al.
Publicado: (2012)

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia
por: Lancet, JE, et al.
Publicado: (2011)

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models
por: Gravina, Giovanni Luca, et al.
Publicado: (2017)

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia
por: Stuart, Robert K, et al.
Publicado: (2015)

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks
por: Hawtin, Rachael Elizabeth, et al.
Publicado: (2010)

Emerging therapies for acute myeloid leukemia
por: Saygin, Caner, et al.
Publicado: (2017)

Differentiation Therapy of Acute Myeloid Leukemia
por: Gocek, Elzbieta, et al.
Publicado: (2011)

Precision therapy for acute myeloid leukemia
por: Yang, Xue, et al.
Publicado: (2018)

Role of autophagy in acute myeloid leukemia therapy
por: Zhang, Su-Ping, et al.
Publicado: (2013)

Advances in targeted therapy for acute myeloid leukemia
por: Yu, Jifeng, et al.
Publicado: (2020)

Resistance to targeted therapies in acute myeloid leukemia
por: Mecklenbrauck, Rabea, et al.
Publicado: (2022)

Targeted Therapy Development in Acute Myeloid Leukemia
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
por: Lin, Min, et al.
Publicado: (2018)

An Overview of Targeted Therapies in Acute Myeloid Leukemia
por: Turkalj, Sven, et al.
Publicado: (2023)

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
por: Kadia, Tapan Mahendra, et al.
Publicado: (2019)

Molecular landscape and targeted therapy of acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2018)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
por: Miyamoto, Kenichi, et al.
Publicado: (2020)

Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy
por: di Martino, Orsola, et al.
Publicado: (2019)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia
por: Obszański, Piotr, et al.
Publicado: (2022)

Recent advances in targeted therapies in acute myeloid leukemia
por: Bhansali, Rahul S., et al.
Publicado: (2023)

Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia
por: Tomizawa, Daisuke, et al.
Publicado: (2023)

Acute Promyelocytic Leukemia Presenting with Severe Marrow Fibrosis
por: Shah, Harsh, et al.
Publicado: (2015)

Immune therapy: a new therapy for acute myeloid leukemia
por: Tian, Chen, et al.
Publicado: (2022)

Angiogenesis in Acute Myeloid Leukemia and Opportunities for Novel Therapies
por: Trujillo, Angelica, et al.
Publicado: (2012)

Maintenance therapy in acute myeloid leukemia: advances and controversies
por: Senapati, Jayastu, et al.
Publicado: (2023)

Prognosis and Therapy When Acute Promyelocytic Leukemia and Other “Good Risk” Acute Myeloid Leukemias Occur as a Therapy-Related Myeloid Neoplasm
por: Larson, Richard A., et al.
Publicado: (2011)

Acute Myeloid Leukemia: Is It T Time?
por: Khoud, Meriem Ben, et al.
Publicado: (2021)

Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy
por: Castelli, Germana, et al.
Publicado: (2017)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2019)

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia
por: Ahmadmehrabi, Khashayar, et al.
Publicado: (2021)

Therapy-related core binding factor acute myeloid leukemia
por: George, Binsah, et al.
Publicado: (2023)

Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment
por: Takahashi, Shinichiro
Publicado: (2023)

Classification of acute myeloid leukemia
por: Hwang, Sang Mee
Publicado: (2020)

Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia
por: Brown, Geoffrey, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j9iutm0uk2v1g48t48liioec00